Implied total company value of up to USD 1 billion, inclusive of 40.8 percent stake currently held by Bayer Initial focus in neurology, cardiology, and immunology with start of first clinical program in Parkinson’s disease expected later this year BlueRock Therapeutics to continue to […]
CAMBRIDGE, Mass., Oct. 26, 2017 — BlueRock Therapeutics, a company developing cellbased therapies designed to alter the course of degenerative disease, today announced the establishment of its corporate headquarters in Cambridge, Massachusetts, as well as the appointment of senior level team members who will support […]
CAMBRIDGE, MA and SEATTLE, WA, October 3, 2017 – BlueRock Therapeutics and Universal Cells Inc. today announced that they have entered into a collaboration and license agreement to create induced pluripotent stem (iPS) cell lines useful for the manufacture of allogeneic cellular therapies. “BlueRock is […]
Formalizes collaborations with McEwen Center for Regenerative Medicine at University Health Network, Centre for Commercialization of Regenerative Medicine Appoints Michael Scott, Ph.D., as Senior Vice President of Product Development and Toronto Operations TORONTO, Ontario and CAMBRIDGE, Mass., August 17, 2017 — BlueRock Therapeutics, which is […]
CEO, CTO and VP of Corporate Development appointments to propel BlueRock’s cell therapy development efforts CAMBRIDGE, Mass., June 27, 2017 — BlueRock Therapeutics today announced a trio of hires that bolster the company’s strategic and operational capabilities to develop breakthrough cell therapies for degenerative diseases […]
BlueRock Therapeutics is focused on breakthrough treatments based on latest stem cell technology in combination with superior cell differentiation protocols BlueRock Therapeutics’ vision is to cure diseases with significant cell loss and diminished self-repair potential with an initial focus on cardiovascular, neurological and other […]
